NASDAQ · Biotechnology · USD

Polaryx Therapeutics, Inc. (PLYX) Stock Analysis

Polaryx Therapeutics, Inc. (PLYX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PLYX

$1.94

+$0.03 (+1.57%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLYX with… →

PLYX Key Statistics

As of Oct 21, 2026

Trading

Open: $1.93
Previous Close: $1.91
Day's Range: 1.85–1.94
52-Week Range: 1.83–48.91
Volume: 13.30K

Valuation

Market Cap: $96.70M
P/E Ratio: unprofitable
EPS (ttm): −0.14

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$8.99M
Shares Outstanding: 49.85M

Dividend and dates

Avg Volume: 69.02K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Polaryx Therapeutics, Inc. (PLYX) has a market capitalization of $96.70M.

In fiscal 2025, PLYX reported revenue of $0.00.

PLYX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$8.99M	—
2024	$0.00	−$30.36M	—
2023	$0.00	−$3.78M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$7.82M	−$8.99M	—
2024	$0.00	—	−$4.35M	−$30.36M	—
2023	$0.00	—	−$3.78M	−$3.78M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Polaryx Therapeutics, Inc. (PLYX) is capitalised at $96.70M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 2 employees.

The most recent close on file for PLYX is $1.94, dated October 21, 2026. That is +$0.03 (+1.57%) against the previous close. Over the past 52 weeks the price has ranged from $1.83 to $48.91. The latest close sits 6.01% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $8.99M. Earnings per share on a trailing basis come to −0.14.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The stored price history starts on February 2, 2026, and the total return since then is −94.46%.

Growth & Income

The record shows no dividend for PLYX.

So far in 2026 the total return is −94.46%.

Peer Comparison

Polaryx Therapeutics, Inc. (PLYX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Polaryx Therapeutics, Inc.	PLYX	$96.70M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Polaryx Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Visit website →